Medical Condition News

RSS

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) of its Athena™ programmer, a deep brain stimulation (DBS) therapy management system.

24 Jan 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced updated Phase 1/2 clinical trial results related to the Company's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the ASCO Gastro Intestinal Cancers Symposium that took place in San Francisco from January 20-22, 2011.

24 Jan 2011

Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry

Alexza Pharmaceuticals, Inc. announced today that the British Journal of Psychiatry, a publication of the Royal College of Psychiatrists, has published the results of the pivotal Phase 3 study evaluating AZ-004 (inhaled or Staccato® loxapine) for the rapid treatment of agitation in patients with schizophrenia, in its January 2011 edition (198:51-58).

24 Jan 2011

Senesco files SNS01-T IND for treatment of multiple myeloma

Senesco Technologies, Inc. today announced that the Company has filed an Investigational New Drug application with the U.S. Food and Drug Administration for Senesco's lead drug candidate SNS01-T for treatment of multiple myeloma.

24 Jan 2011

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Boston Scientific Corporation today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary Stent. The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element™ Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion.

24 Jan 2011

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

The Methodist DeBakey Heart & Vascular Center was chosen today as a site for a critical percutaneous heart valve study. As part of the research study, Methodist physicians will replace diseased cardiac valves through a single, tiny puncture hole in the research subject's groin.

24 Jan 2011

NHLBI, HeartWare award $13.3M to study benefits of heart devices for heart failure

The University of Michigan Cardiovascular Center and the University of Pittsburgh have been awarded $13.3 million to explore the potential benefits of heart devices for the large and growing group of Americans with heart failure.

24 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

Rogue gene blocked by right drugs could stop cancer

Scientists at the University of East Anglia (UEA) have discovered a rogue gene which - if blocked by the right drugs - could stop cancer in its tracks.

24 Jan 2011

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have made a breakthrough in understanding the mechanisms behind the most severe form of hereditary emphysema and how protein treatments can improve the condition. The findings of this study may also lead to new treatments for patients with smoker's emphysema.

24 Jan 2011

Contagious cancer repairs own genetic mutations

A curious contagious cancer, found in dogs, wolves and coyotes, can repair its own genetic mutations by adopting genes from its host animal, according to a new study in the journal Science.

24 Jan 2011

Mathematical models to predict fatigue could reduce risk of accidents

Washington State University sleep researchers have determined that the air traffic controller in the crash of a Lexington, Ky., commuter flight was substantially fatigued when he failed to detect that the plane was on the wrong runway and cleared it for takeoff.

24 Jan 2011

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor Pharmaceutical Corp., today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Jan 2011

Nutrient 'biomarkers' may help assess nutrient status of elderly people at risk for dementia

Research is trying to determine whether Alzheimer's disease might be slowed or prevented with nutritional approaches, but a new study suggests those efforts could be improved by use of nutrient "biomarkers" to objectively assess the nutrient status of elderly people at risk for dementia.

24 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

R-Tech Ueno announces completion of RK-023 Phase 2a study for androgenetic alopecia

R-Tech Ueno, is pleased to announce that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia was completed by January 21, 2011.

24 Jan 2011

Psychological Science journal releases new research findings

The insula has been implicated in evaluative and affective processes. New findings indicate that the insula may be broadly involved in integrating affective and cognitive processes. Participants rated the positivity and negativity of picture stimuli and how emotionally arousing they found the pictures to be.

24 Jan 2011

Medical Condition News

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry

Senesco files SNS01-T IND for treatment of multiple myeloma

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

NHLBI, HeartWare award $13.3M to study benefits of heart devices for heart failure

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Rogue gene blocked by right drugs could stop cancer

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Contagious cancer repairs own genetic mutations

Mathematical models to predict fatigue could reduce risk of accidents

KineMed's fibrosis research program featured in Nature Medicine

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Nutrient 'biomarkers' may help assess nutrient status of elderly people at risk for dementia

FDA approves Clinical Data's Viibryd for major depressive disorder

R-Tech Ueno announces completion of RK-023 Phase 2a study for androgenetic alopecia

Psychological Science journal releases new research findings

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News